Physicians' Academy for Cardiovascular Education

Fewer major CV events in patients on ARBs compared to ACEi in high-risk patients

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk

Literature - Potier L, Roussel R, Elbez Y, et al. - Heart 2017, Epub ahead of print

Main results


Compared to ACEi, ARB use was associated with a lower rate of major CV events in outpatients with high CV risk, which was consistent using two multiple adjustment methods. This difference between ARB and ACEi use was only significant in the subgroup of patients with established atherosclerosis. These results suggest that ARBs should be preferred over ACEIs in patients with a previous history of CV diseases.


Show references

Find this article online at Heart

Share this page with your colleagues and friends: